Clinical trial • Phase III • Neurology
Clinical trial in Chronic pain | Pain
Phase III trial for Chronic pain | Pain. 16 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Chronic pain | Pain
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 17-04-2025
- First CTIS Authorization Date
- 23-05-2025
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 16
Eligibility
Recruits 16 Vulnerable population not selected; participants are healthy volunteers; no special consent/assent handling stated..
- Vulnerable Population
- Vulnerable population not selected; participants are healthy volunteers; no special consent/assent handling stated.
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 3
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Belgium
- Earliest CTIS Part Ii Submission Date
- 15-05-2025
- Latest Decision Or Authorization Date
- 23-05-2025
- Processing Time Days
- 8
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- DRUG
- Contact Person Name
- Sylvie Rottey
- Contact Person Email
- sylvie.rottey@uzgent.be
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke